Navigation Links
Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
Date:6/24/2011

atients in their efforts to achieve and sustain glycemic control.(vi,vii)

About BYETTA® (exenatide) injection

BYETTA was the first glucagon-like peptide-1 (GLP-1) receptor agonist to be approved by the FDA for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone GLP-1. GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not currently recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis. BYETTA has not been studied in people who have pancreatitis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss (BYETTA is not a weight-loss product). BYETTA was approved in the U.S. in April 2005 and in Europe in November 2006 and has been used by more than 1.8 million patients since its introduction. See important safety information below. Additional information about BYETTA is available at www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection

Based on postmarketing data BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Patients should be observed for signs and symptoms of pancreatitis after initiation or dose escalation of BYETTA. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who ha
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
3. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
4. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
5. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
6. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
7. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
8. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
10. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
11. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced the ... : North American Automated External Defibrillators ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report North ... analyzes the market of devices based ...
(Date:10/17/2014)... 2014 Investor-Edge has initiated coverage ... ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ), and ... these five companies can be accessed at: http://investor-edge.com/register ... 16, 2014, ended on a mixed note as the ...
(Date:10/17/2014)... KIRKLAND, Wash. , Oct. 17, 2014  Talyst, ... at the 2014 LeadingAge Annual Meeting in ... its InSite System, the market leading solution for onsite, ... enables long term care facilities to safely and securely ... on time to first dose, helps ensure that the ...
Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2
... N.J., Oct. 8 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... 4,300,000 shares of its common stock at a price of ... estimated offering expenses, Savient expects to receive net proceeds of ... sold by Savient. In addition, Savient has granted the ...
... Oct. 8 BALTIMORE CONVENTION CENTER / BOOTH ... of emergency department (ED) clinical documentation solutions, today announced ... ® electronic Emergency Department Information System (EDIS) incorporates ... facilitate the diagnosis and treatment of H1N1, as well ...
Cached Medicine Technology:Savient Pharmaceuticals Prices Underwritten Offering of Common Stock 2Latest Content Release for The T SystemEV EDIS Supports Clinicians in Providing Quality Care for H1N1 Patients 2Latest Content Release for The T SystemEV EDIS Supports Clinicians in Providing Quality Care for H1N1 Patients 3
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... Problems With Governor,s Mandatory Health Insurance Plan, ... today by the Schwarzenegger Administration fail to,protect patients ... decide which policies to cancel without prior review ... Consumer Rights (FTCR).,FTCR said that the weak cancellation ...
... Inc., an investment,company with a series of 20 ... by Standard & Poor,s, the calculating agent for ... trading on,Friday, October 26, 2007, Immunogen, Inc. (Nasdaq: ... BIVN ) in the HealthShares(TM) Emerging Cancer,Index. Bioenvision, ...
... Offers Tips for People with Diabetes Affected ... by California Wildfires, ... the following tips for people with diabetes who,are affected by the ... with diabetes,require additional supplies to manage their health. 1) Medication ...
... on November 13, 2007 at 8:00 am ... 9:00 pm (Beijing/Hong Kong), SHANGHAI, China, Oct. 23 ... ("WuXi PharmaTech" or "the Company"), the leading,China-based pharmaceutical and ... will release unaudited,financial results for the third quarter ended ...
... PDT (8:00 p.m. EDT), SUNNYVALE, Calif., Oct. 23 ... field of radiosurgery,announced today that it will host an investor ... the American Society of,Therapeutic Radiology and Oncology (ASTRO) in Los ... PDT. A live webcast of the presentation will begin ...
... -- Mayo Clinic today reported promising interim results from ... for patients with recurrent ovarian cancer that is resistant ... either complete or partial tumor regression from the therapy, ... this Phase 2 Consortium (P2C) clinical trial were presented ...
Cached Medicine News:Health News:Draft Rules Won't Stop Insurers' Illegal Cancellations of Health Policies 2Health News:Draft Rules Won't Stop Insurers' Illegal Cancellations of Health Policies 3Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index 3Health News:Emergency Preparedness for People With Diabetes 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 3Health News:Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007 2Health News:Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007 3Health News:Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer 2
... For the quantitative determination of ... ,Patients with atopic allergic diseases such ... fever have been shown to exhibit ... blood. IgE is also known as ...
...
...
...
Medicine Products: